奥希替尼联合放疗对EGFR基因突变晚期NSCLC患者血清PCNA、TSGF水平和预后的影响  

Effect of ositinib combined with radiotherapy on serum PCNA,TSGF and prognosis in advanced NSCLC patients with EGFR mutation

作　　者：张林 赵玉魁 ZHANG Lin;ZHAO Yu-kui(Department of Radiotherapy II,Wanbei Coal and Power Group General Hospital,Suzhou 234000,Anhui,China)

机构地区：[1]皖北煤电集团总医院放疗二科,安徽宿州234000

出　　处：《川北医学院学报》2023年第3期399-402,共4页Journal of North Sichuan Medical College

基　　金：蚌埠医学院自然科学基金(2020byzd356)。

摘　　要：目的:探讨奥希替尼联合放疗对表皮生长因子受体(EGFR)基因突变晚期非小细胞肺癌(NSCLC)患者血清细胞增殖抗原(PCNA)、肿瘤特异性生长因子(TSGF)和预后的影响。方法:根据治疗方案不同将100例EGFR基因突变晚期NSCLC患者分为联合组与对照组,每组各50例;联合组予以奥希替尼联合放疗治疗,对照组予以单药奥希替尼治疗。比较两组近期疗效、远期生存期、治疗前和治疗3个月后细胞角蛋白19片段(CYFRA21-1)、糖类抗原125(CA125)和PCNA、TSGF表达及不良反应发生情况。结果:联合组的客观缓解率高于对照组,但差异无统计学意义(P>0.05)。治疗3个月后,联合组血清CYFRA21-1、CA125和PCNA、TSGF水平均低于对照组(P<0.05)。患者随访6~36个月,联合组中位无进展生存期、总生存期分别为14.9个月、25.2个月,优于对照组的10.1个月、18.8个月,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:奥希替尼联合放疗治疗EGFR基因突变晚期NSCLC可有效降低血清PCNA、TSGF水平,改善患者生存预后,且不增加不良反应。Objective:To investigate the effect of ositinib combined with radiotherapy on serum proliferating cell nuclear antigen(PCNA),tumor specific growth factor(TSGF)and prognosis in advanced non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)gene mutation.Methods:A total of 100 patients with advanced NSCLC with EGFR gene mutation were enrolled.According to different treatment schemes,they were divided into combined group and control group,with 50 cases in each group.The combination group was treated with ositinib combined with chemotherapy,and the control group was treated with single drug ositinib.The short-term efficacy and long-term survival time of the two groups were compared.The cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 125(CA125),PCNA and TSGF were measured before treatment and 3 months after treatment,and the adverse reactions of the two groups were observed and compared.Results:The objective remission rate of the combined group was higher than that of the control group,but the difference was not statistically significant(P>0.05).After 3 months of treatment,the serum CYFRA21-1,CA125,PCNA and TSGF levels in the combined group were lower than those in the control group(P<0.05).Patients were followed up for 6~36 months.The median PFS and OS in the combined group were 14.9 months and 25.2 months,respectively,which were better than those in the control group(10.1 months and 18.8 months),and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Ositinib combined with radiotherapy in the treatment of advanced NSCLC with EGFR gene mutation can effectively reduce the levels of serum PCNA and TSGF,improve the survival prognosis of patients without increasing adverse reactions.

关 键 词：非小细胞肺癌 表皮生长因子受体-酪氨酸激酶抑制剂 奥希替尼 细胞增殖抗原 肿瘤特异性生长因子 生存期 

分 类 号：R734.2[医药卫生—肿瘤]